Evidence map›Paper›PMID 35430141›Full record

Observational studyJournal of cardiology2022

The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study.

Yuji Nishimoto, Sen Yachi, Makoto Takeyama, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa and 14 more

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Guideline
  2. Efficacy and Safety of Direct Oral Anticoagulants Compared With Heparin for Preventing Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  3. Article
  4. Article
  5. Long-term Cardiovascular, Cerebrovascular, and Other Thrombotic Complications in COVID-19 Survivors: A Retrospective Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 1 country.

Yuji NishimotoHyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Sen YachiJapan Community Health Care Organization Tokyo Shinjuku Medical Center, Tokyo, Japan.
Makoto TakeyamaJapan Community Health Care Organization Tokyo Shinjuku Medical Center, Tokyo, Japan.
Ichizo TsujinoHokkaido University Hospital, Sapporo, Japan.
Junichi NakamuraHokkaido University Hospital, Sapporo, Japan.
Naoto YamamotoHamamatsu Medical Center, Hamamatsu, Japan.
Hiroko NakataYokosuka General Hospital Uwamachi, Yokosuka, Japan.
Satoshi IkedaNagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Michihisa UmetsuTohoku University Hospital, Sendai, Japan.
Shizu AikawaTsukuba Medical Center Hospital, Tsukuba, Japan.
Hiroya HayashiOsaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Hirono SatokawaFukushima Medical University, School of Medicine, Fukushima, Japan.
Yoshinori OkunoKyoto University Hospital, Kyoto, Japan.
Eriko IwataNankai Medical Center Japan Community Health Care Organization, Saiki, Japan.
Yoshito OgiharaMie University Hospital, Tsu, Japan.
Nobutaka IkedaToho University Ohashi Medical Center, Tokyo, Japan.
Akane KondoShikoku Medical Center for Children and Adults, Zentsuji, Japan.
Takehisa IwaiTsukuba Vascular Center, Ibaraki, Japan.
Norikazu YamadaKuwana City Medical Center, Kuwana, Japan.
Tomohiro OgawaFukushima Daiich Hospital, Fukushima, Japan.
Takao KobayashiHamamatsu Medical Center, Hamamatsu, Japan.
Makoto MoYokohama Minami Kyosai Hospital, Yokohama, Japan.
Yugo YamashitaKyoto University Hospital, Kyoto, Japan. Electronic address: yyamashi@kuhp.kyoto-u.ac.jp.
CLOT-COVID Study Investigators
Hamamatsu Medical Center · JPHokkaido University Hospital · JPKyoto University Hospital · JPTokyo Yamate Medical Center · JPTsukuba Medical Center Hospital · JPFukushima Medical University · JPFukushima Medical University Hospital · JPHyogo Prefectural Amagasaki General Medical Center · JPMie University Hospital · JPNagasaki University · JPNaval Hospital Yokosuka Japan · JPOsaka Metropolitan UniversityShikoku Medical Center for Children and Adults · JPSunagawa City Medical Center · JPTohoku University Hospital · JPToho University · JPYokohama Minami Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundData on thrombosis and current real-world management strategies for anticoagulation therapy are scarce but important for understanding current issues and unmet needs of an optimal management of patients with coronavirus disease 2019 (COVID-19).

methodThe CLOT-COVID Study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800) was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021, and we tried to capture the status of the patients in the fourth and fifth waves of the COVID-19 infections in Japan. We enrolled consecutive hospitalized patients who were diagnosed with COVID-19 and had a positive polymerase chain reaction test obtained from the hospital databases.

resultsAmong 2894 patients with COVID-19, 1245 (43%) received pharmacological thromboprophylaxis. The proportion of pharmacological thromboprophylaxis increased according to the severity of the COVID-19 in 9.8% with mild COVID-19, 61% with moderate COVID-19, and 97% with severe COVID-19. The types and doses of anticoagulants varied widely across the participating centers. During the hospitalization, 38 patients (1.3%) and 126 (4.4%) underwent ultrasound examinations for the lower extremities and contrast-enhanced computed tomography examinations, respectively, and 55 (1.9%) developed thrombosis, mostly venous thromboembolism (71%). The incidence of thrombosis increased according to the severity of the COVID-19 in 0.2% with mild COVID-19, 1.4% with moderate COVID-19, and 9.5% with severe COVID-19. Major bleeding occurred in 57 patients (2.0%) and 158 (5.5%) died, and 81% of them were due to respiratory failure from COVID-19 pneumonia.

conclusionsIn the present large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients with COVID-19 was common especially in patients with severe COVID-19, and management strategies varied widely across the participating centers. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19.

Indexed as

COVID-19ThrombosisVenous ThromboembolismAnticoagulantsCohort StudiesHumansJapanRetrospective StudiesSARS-CoV-2AnticoagulantsAnticoagulantsAsianCoronavirus disease 2019JapanThrombosis

Identifiers

PMID35430141
PMCPMC8979768
OpenAlexW4224087588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.